Gossamer Bio (NASDAQ:GOSS) Upgraded to “Strong-Buy” at Barclays

Gossamer Bio (NASDAQ:GOSS) was upgraded by equities researchers at Barclays to a “strong-buy” rating in a research report issued on Tuesday,Zacks.com reports.

Several other research analysts also recently commented on GOSS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Gossamer Bio in a report on Thursday, January 22nd. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Gossamer Bio in a research note on Thursday, January 22nd. Finally, Wall Street Zen downgraded Gossamer Bio from a “hold” rating to a “sell” rating in a research note on Friday, January 23rd. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $8.60.

Gossamer Bio Price Performance

Shares of NASDAQ GOSS opened at $2.55 on Tuesday. Gossamer Bio has a one year low of $0.76 and a one year high of $3.87. The business’s fifty day moving average price is $3.07 and its 200-day moving average price is $2.62. The stock has a market capitalization of $590.22 million, a PE ratio of -3.70 and a beta of 1.92.

Gossamer Bio (NASDAQ:GOSS) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.02). The firm had revenue of $13.29 million during the quarter, compared to analysts’ expectations of $6.32 million. Gossamer Bio had a negative return on equity of 1,774.72% and a negative net margin of 354.50%. As a group, equities analysts expect that Gossamer Bio will post -0.28 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Legal & General Group Plc purchased a new position in Gossamer Bio in the 2nd quarter worth approximately $26,000. Ciovacco Capital Management LLC purchased a new position in shares of Gossamer Bio in the 3rd quarter worth about $27,000. Banco BTG Pactual S.A. bought a new position in shares of Gossamer Bio during the 2nd quarter valued at about $27,000. Drive Wealth Management LLC raised its holdings in shares of Gossamer Bio by 52.7% during the 2nd quarter. Drive Wealth Management LLC now owns 25,474 shares of the company’s stock valued at $31,000 after buying an additional 8,797 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in Gossamer Bio in the fourth quarter worth approximately $35,000. 81.23% of the stock is currently owned by institutional investors.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.